$0.54
+0.05 (+11.07%)
AVX News3 articles
Novavax Shares Surge on Pfizer Deal, Vaccine Strategy Shift
Novavax shares surged 13% Friday after Q1 revenue of $139.5 million beat estimates, fueled by a $30 million Pfizer licensing deal for Matrix-M adjuvant.
Novavax Surges on Pfizer Deal, Q1 Revenue Beat Despite Weak Vaccine Sales
Novavax reported Q1 revenue of $139.5M, beating estimates, driven by $30M from Pfizer's Matrix-M license. Shares rose further as licensing income offset weak COVID vaccine sales.
Novavax Surges on Pfizer Deal, Beats Q1 Revenue Forecasts
Novavax topped Q1 revenue estimates at $139.5M, driven by a $30M Pfizer payment, offsetting weak COVID vaccine sales. Shares rose 15.6%.